Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guillaume Grzych has a total of 173 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Étude du profil métabolomique des patients atteints de stéatose hépatique non alcoolique (NASH) : recherche d’hypothèses physiopathologiques et de biomarqueurs

    by Guillaume Grzych

    La NAFLD (Non Alcoholic Fatty Liver Disease), enjeu majeur de santé publique, est la complication hépatique du syndrome métabolique. La NAFLD se caractérise par des lésions hépatiques dues à une accumulation de triglycérides dans le foie qui, associée à une inflammation, évolue vers la stéato-hépatite (NASH Non-Alcoholic Steatohepatitis). Les mécanismes moléculaires sous-tendant la pathogenèse et particulièrement le passage de la stéatose à la NASH sont encore mal compris. Une meilleure compréhension de la physiopathologie de la NASH est nécessaire afin d’identifier de potentielles cibles thérapeutiques et des marqueurs non invasifs pour le diagnostic et le suivi de la pathologie.Dans ce contexte, la métabolomique apparait prometteuse. La métabolomique est l'analyse de l'ensemble des métabolites dans un milieu biologique et complète les autres techniques «omics» pour l'étude des propriétés biologiques dynamiques. Ce travail a pour objectif d’utiliser l’approche métabolomique pour mettre en évidence un profil particulier chez les patients atteints de NASH afin de comprendre la physiopathologie et d’identifier de potentiels biomarqueurs. Pour cela, nous avons utilisé deux approches métabolomiques : 1/ l’approche ciblée, sur plasma, en se focalisant sur deux classes de métabolites, les acides aminés et les acides biliaires, 2/ l’approche non ciblée sur plasmas et foies humains (dont les résultats sont en attente). Dans la littérature, les acides biliaires (AB) sont étudiés en tant qu'acteurs physiopathologiques et biomarqueurs dans la NASH. Cependant, l'interprétation des résultats est compliquée par l'association étroite de la NASH avec le diabète de type 2 (DT2), la résistance à l'insuline (IR) et l'obésité, contextes métaboliques qui sont aussi associés à des variations d’AB. Nous avons donc cherché à comprendre la relation complexe entre la NASH et les concentrations d’AB, en fonction du statut DT2, et en tenant compte de l’IR et de l’obésité. Par analyses des profils d’AB dans deux cohortes (ABOS n=219, RESOLVE n=58) de patients obèses bien caractérisés (biopsies hépatiques, statut clinico-biologique, effectif élevé), nous montrons que les concentrations plasmatiques des AB sont plus élevés chez les patients NASH vs non-NASH, à la fois chez les patients DT2 et Non-DT2. Par contre, ces augmentations dépendent du degré d’IR, ce qui suggère que la NASH n'entraîne des altérations d’AB qu'en présence d'une IR avancée et indépendamment du statut diabétique.Dans la littérature, les concentrations plasmatiques d’AA à chaîne ramifiée (BCAA) sont associées avec l’obésité, l’IR et la gravité des lésions hépatiques de la NAFLD. De plus, les concentrations plasmatiques de BCAA diffèrent entre les sexes, qui présentent des susceptibilités différentes aux maladies cardiométaboliques. Nous avons évalué l’association entre les concentrations plasmatiques de BCAA et les stades de gravité de la NAFLD,indépendamment du sexe, de l’IR et de l’obésité. Dans la cohorte RESOLVE, 112 patients obèses ont été divisés en quatre groupes en fonction de la sévérité de la NAFLD, et appariés en fonction du sexe, de l'IMC, de l'IR et de l'HbA1c. Comme attendu, une corrélation positive modeste a été observée entre les concentrations de BCAA et la sévérité de la NAFLD, ainsi qu'un impact majeur du sexe sur les concentrations de BCAA. L'analyse des sous-groupes révèle que, si les concentrations plasmatiques de BCAA augmentent avec la sévérité de la NAFLD chez les femmes, elles ont tendance à diminuer chez les hommes, suggérant un impact du sexe sur la composante métabolique de la NAFLD

  • Addressing the silent epidemic of recreational nitrous oxide use: a position, call to action and recommendations by the European Federation of Clinical Chemistry and Laboratory Medicine Committee on Biological Markers of Nitrous Oxide Abuse

    by Guillaume Grzych, Graham R. Lee, Medine Alpdemir, Emeline Gernez, Kurt Anseeuw, Anne-Lise Bjorke-Monsen, Kathleen Croes, Joe M. El-Khoury, Jasmin Hamzic, Alastair J. Noyce, et al.

    Recreational nitrous oxide (N 2 O) use has emerged as a growing public health concern, with increasing reports of neurological, psychiatric, and thrombotic complications. This position paper from the EFLM Committee on Biological Markers of Nitrous Oxide Abuse highlights the urgent need for clinical and laboratory awareness, alongside coordinated action from healthcare systems and the scientific community. Short-term recommendations focus on early clinical recognition, prompt biological testing, and structured patient management. Key clinical symptoms include unexplained sensory disturbances, gait instability, bladder and bowel complaints, sexual dysfunction, mood disorders, and thromboembolic events in young individuals. Plasma homocysteine (HCY) and plasma methylmalonic acid (MMA) are central to the diagnostic approach, with HCY serving as a sensitive marker of recent exposure and MMA indicating clinical severity. Vitamin B12 and folate measurements are also essential, though B12 levels may be falsely reassuring (often in the low-normal range). Given the rapid normalization of biomarkers, testing should be performed on admission, and vitamin B12 supplementation should begin without delay, with caution regarding biomarker kinetics and possible self-supplementation by patients. In addition, this paper outlines long-term goals, including the harmonization of biomarker assays, creation of international patient registries, and development of interdisciplinary expert networks. Notably, the international network PROTOSIDE ( www.protoside.com ) plays a key role in facilitating case discussion, expert collaboration, and dissemination of best practices in the management of N 2 O-related complications. A continuous bibliographic watch and support for translational research are necessary to improve biomarker discovery and understanding of the underlying mechanisms of toxicity. By combining immediate clinical action with long-term scientific and policy development, this document lays the foundation for an international strategy to address the silent but expanding epidemic of nitrous oxide misuse.


  • Innovative closed tube protocol reveals a super critical early preanalytical phase of whole blood glucose stability in routine matrices

    by Guillaume Grzych, Arnaud Pinsart, Inès Defauwes, Manon Campas, Elodie Grifnée, Pascal de Tullio, Etienne Cavalier

  • Open Access

    Addressing the Global Challenge of Nitrous Oxide Misuse Through a Multidisciplinary Approach: Example of the PROTOSIDE Network

    by Guillaume Grzych, Remy Diesnis, Thierry Dupré, Jean Paul Niguet, Emeline Gernez, Damien Denimal, Sylvie Deheul, Jean Claude Guichard, Damien Scliffet, Bruno Mégarbane, et al.

    Nitrous oxide (N2O) was originally used for medical and industrial purposes, but its recreational use has dramatically increased, raising a major global public health concern. Chronic inhalation is associated with neurological, metabolic, and psychiatric complications, as well as addiction. To address these challenges, the PROTOSIDE network was developed to provide a multidisciplinary approach to management and prevention. This initiative relies on competence centers integrating specialists in emergency medicine, neurology, clinical biochemistry, and addiction medicine. PROTOSIDE aims to standardize diagnostic protocols, optimize patient care pathways, and strengthen addictovigilance. A strong emphasis is placed on prevention, including awareness campaigns and collaboration with healthcare professionals and educators. By facilitating access to advanced biochemical analyses (homocysteine, methylmalonic acid) and promoting international guidelines, PROTOSIDE represents an innovative model for a global response to N2O misuse. This integrated approach enhances clinical management, reduces complications, and harmonizes public health strategies.


  • Open Access

    Enhancing Differential Diagnosis Related to Oxidative Stress, Nitrous Oxide, and Nutrition by Rapid Plasma Homocysteine Measurement

    by Guillaume Grzych, Farid Zerimech, Benjamin Touze, Clarence Descamps, Marie-Adélaïde Bout, Marie Joncquel, Claire Douillard, Isabelle Kim, Céline Tard, Thierry Brousseau

    Background: Historically used as a marker for inherited disorders, the current interest in plasma homocysteine measurement lies in its ability to provide valuable information about the metabolic and nutritional status of patients. Specifically, nitrous oxide (N2O) abuse can lead to functional vitamin B12 deficiency by oxidation and increase oxidative stress, resulting in elevated plasma homocysteine levels, which mimic neurological conditions such as Guillain–Barré syndrome. Rapid identification of hyperhomocysteinemia is crucial for timely intervention and avoiding costly, unnecessary treatments. Objective: This study evaluates the performance of a rapid immunoassay technique (Snibe) compared to mass spectrometry (LC-MS/MS) for measuring plasma homocysteine levels in patients with nitrous oxide abuse and non-inherited caused of elevated homocysteine, aiming to enhance differential diagnosis related to oxidative stress. Methods: 235 patients from Lille University Hospital were included. EDTA blood samples were collected and analyzed using both rapid immunoassay (Snibe) and LC-MS/MS. Neurological assessment was performed using the peripheral neuropathy disability (PND) score. Results: Firstly, significant elevations in plasma homocysteine levels were observed in patients abusing nitrous oxide measured by LC-MS/MS. Secondly, the immunoassay provided rapid results, essential for early clinical decision-making, but tended to underestimate high values compared to LC-MS/MS. A good correlation was found between the methods for low and moderate values. Conclusion: The immunoassay tended to underestimate high-value samples compared to LC-MS/MS, which is a common problem with the competitive methodology. The rapid immunoassay technique is effective for initial screening and early intervention, aiding in the differential diagnosis of conditions related to oxidative stress. Therefore, it is recommended to use the CLIA method for initial screening and confirm with mass spectrometry if there are abnormal samples. Integrating both techniques can enhance diagnostic accuracy and improve patient outcomes.


  • Nitrous oxide abuse direct measurement for diagnosis and follow-up: update on kinetics and impact on metabolic pathways

    by Angèle Lucas, Alastair J. Noyce, Emeline Gernez, Joe M. El Khoury, Guillaume Garcon, Etienne Cavalier, Sébastien Antherieu, Guillaume Grzych

    Recreational use of nitrous oxide (N2O) has become a major health issue worldwide, with a high number of clinical events, especially in neurology and cardiology. It is essential to be able to detect and monitor N2O abuse to provide effective care and follow-up to these patients. Current recommendations for detecting N2O in cases of recreational misuse and consumption markers are lacking. We aimed to update current knowledge through a review of the literature on N2O measurement and kinetics. We reviewed the outcomes of experiments, whether in preclinical models (in vitro or in vivo), or in humans, with the aim to identify biomarkers of intoxication as well as biomarkers of clinical severity, for laboratory use. Because N2O is eliminated 5 min after inhalation, measuring it in exhaled air is of no value. Many studies have found that urine and blood matrices concentrations are connected to ambient concentrations, but there is no similar data for direct exposure. There have been no studies on N2O measurement in direct consumers. Currently, patients actively abusing N2O are monitored using effect biomarkers (biomarkers related to the effects of N2O on metabolism), such as vitamin B12, homocysteine and methylmalonic acid.


  • Open Access

    Understanding Neuropathy Features in the Context of Nitrous Oxide Abuse: A Combined Electrophysiological and Metabolic Approach

    by Guillaume Grzych, Marie Scuccimarra, Laura Plasse, Emeline Gernez, Francois Cassim, Benjamin Touze, Marie Girot, Cécile Bossaert, Céline Tard

    Background: The incidence of neurological complications associated with nitrous oxide (N2O) abuse, including N2O-induced myelopathy and neuropathy, has risen in the past decade. N2O-induced neuropathy often presents as a subacute axonal pathology; however, demyelinating patterns mimicking Guillain–Barré syndrome have also been observed. This study explores the metabolic pathophysiology of N2O-induced neuropathy, focusing on the alteration in metabolism to provide a deeper understanding of the biochemical pathways influencing the diverse electrophysiological patterns observed. Methods: We conducted a combined metabolic and electrophysiological exploration of 35 patients who underwent electromyographic exams at our referral center over a three-year period for sensorimotor symptoms linked to recreational N2O use. We collected demographic, clinical, radiological, electrophysiological, and biological data. Patients were categorized into axonal or demyelinating groups based on their electrophysiological patterns, and metabolic parameters were compared. Results: Our cohort predominantly exhibited a length-dependent sensorimotor axonal symmetrical neuropathy affecting the lower limbs. Among the patients, 40% met the demyelinating criteria, with four patients exhibiting conduction blocks. The demyelinating group had a significantly higher peripheral neuropathy disability (PND) score at diagnosis. Elevated homocysteine and methylmalonic acid (MMA) levels were noted in all patients, but these were lower in the demyelinating group. Conclusions: This study highlights the diverse electrophysiological manifestations of N2O-induced neuropathy and underscores the potential role of metabolic parameters as biomarkers to understand its pathophysiology. Lower hyperhomocysteinemia and MMA levels were observed in demyelinating patterns. In this study, we did not observe further improvement, but it is well-known that demyelinating features have a better prognosis related to the further remyelination. These findings contribute to a better understanding of N2O-related neuropathic damage and could guide future therapeutic interventions based on biochemical–neurophysiological stratifications.


  • Open Access

    What biological markers could be used for diagnosis and monitoring of nitrous oxide abuse?

    by Emeline Gernez, Angèle Lucas, Jean‐Paul Niguet, Anas Bennis, Remy Diesnis, Alastair J. Noyce, Guillaume Grzych


  • Open Access

    Nitrous Oxide Abuse: Clinical Outcomes, Pharmacology, Pharmacokinetics, Toxicity and Impact on Metabolism

    by Emeline Gernez, Graham Robert Lee, Jean-Paul Niguet, Farid Zerimech, Anas Bennis, Guillaume Grzych

    The recreational use of nitrous oxide (N2O), also called laughing gas, has increased significantly in recent years. In 2022, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) recognized it as one of the most prevalent psychoactive substances used in Europe. Chronic nitrous oxide (N2O) exposure can lead to various clinical manifestations. The most frequent symptoms are neurological (sensitive or motor disorders), but there are also other manifestations like psychiatric manifestations or cardiovascular disorders (thrombosis events). N2O also affects various neurotransmitter systems, leading to its anesthetic, analgesic, anxiolytic and antidepressant properties. N2O is very challenging to measure in biological matrices. Thus, in cases of N2O intoxication, indirect biomarkers such as vitamin B12, plasma homocysteine and plasma MMA should be explored for diagnosis and assessment. Others markers, like oxidative stress markers, could be promising but need to be further investigated.